Extensions

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is granted to compensate for delays by the USPTO during the prosecution of a utility or plant patent application. This adds time to the standard 20-year patent term from the earliest filing date. Common delays include failure to issue a first office action within 14 months, failure to respond to an applicant's reply within four months, failure to issue a patent within four months of the issue fee payment, or if the patent is not issued within three years from the filing date. Applicant delays can reduce any PTA awarded.

The Google Patents record for US12030959B1 indicates an "Anticipated expiration" date of 2043-07-20. Given the filing date of October 12, 2023, the standard 20-year term would typically end on October 12, 2043. The difference between these dates (approximately 9 months and 8 days) suggests that Patent Term Adjustment (PTA) has likely been applied to US12030959. However, the specific calculation and reasons for this adjustment are not detailed in the provided Google Patents snippet. To obtain the precise PTA calculation, one would need to access the official patent prosecution history from the USPTO Patent Center.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is available under the Hatch-Waxman Act (35 U.S.C. § 156) for patents claiming products, methods of using products, or methods of manufacturing products that require regulatory approval prior to commercial marketing or use. This typically applies to human drug products, medical devices, food additives, or color additives, and aims to restore a portion of the patent term lost during the regulatory review process. The maximum PTE is generally five years, and the extended term cannot exceed 14 years from the date of marketing approval.

As of the current date (April 26, 2026), there is no information in the provided patent text or search results to indicate that a Patent Term Extension (PTE) has been applied for or granted for US12030959. A PTE application must be filed within 60 days of the mailing date of marketing approval of the product. Since omalizumab for food allergies is a new indication, a PTE may be pursued once FDA approval is granted for this specific use.

Continuation and Divisional Applications

• Continuation Application: A continuation application is a second application for the same invention claimed in a prior nonprovisional application, filed before the patenting or abandonment of the prior application.
• Divisional Application: A divisional application results from a restriction requirement made by the USPTO, where multiple distinct inventions were claimed in a single parent application.

The Google Patents record for US12030959B1 lists the following priority claims:

• Priority claimed from PCT/US2023/070639 (2023-07-20). This indicates that US12030959 is likely a national stage entry of this PCT application.
• Priority to US18/486,053 (2023-10-12). This is the application number for US12030959B1 itself, also listed as the filing date, suggesting it is the direct application leading to this patent.
• Priority to US19/050,002 (2025-02-10). This indicates that a later-filed application, US19/050,002, claims priority to US12030959. This later application is likely a continuation or divisional application of US12030959. Without access to the specific nature of US19/050,002, it is not possible to definitively state whether it is a continuation, divisional, or continuation-in-part.

Related Family Members

Based on the priority claims listed, the following are related family members:

• PCT/US2023/070639: An international patent application.
• US19/050,002: A later-filed U.S. patent application that claims priority to US12030959B1. This would be considered a direct family member.
• WO2025010086A1: This is the publication number for the PCT application PCT/US2023/070639.

Projected Expiration Date

The Google Patents record for US12030959B1 indicates an "Anticipated expiration" date of 2043-07-20. This date includes any Patent Term Adjustment (PTA) granted for delays during prosecution. This differs from the typical 20-year term from the filing date of October 12, 2023, which would result in an expiration of October 12, 2043, implying approximately 9 months and 8 days of PTA. This date does not include any potential Patent Term Extension (PTE) under 35 U.S.C. § 156, which would be granted due to regulatory review delays for a pharmaceutical product.